KR20230165006A - Apparatus and medhod for treating orthopedic diseases using bioactive and biodegradable material - Google Patents

Abstract

Disclosed is a device and method for treating orthopedic diseases using bioactive and biodegradable materials. The implant according to the present invention includes a case placed in an area of the spine where an intervertebral disc is provided; and a carrier provided in the internal space of the case, which absorbs the liquid bone formation protein and allows it to be eluted to the treatment area.

Description

Apparatus and method for treating orthopedic diseases using bioactive and biodegradable materials {APPARATUS AND MEDHOD FOR TREATING ORTHOPEDIC DISEASES USING BIOACTIVE AND BIODEGRADABLE MATERIAL}

The present invention relates to a device and method that can treat spinal diseases and other related musculoskeletal and nervous system diseases using new materials and biological activities to prevent spinal metastatic cancer cell proliferation.

As the population transitions into an aging society, the number of patients with spinal diseases such as intervertebral stenosis, intervertebral disc herniation, and posterior joint hypertrophy is rapidly increasing, and research on treatments is also active. Spinal implants are used in fusion surgery, which has been used for a long time among the surgical treatment methods for degenerative spinal diseases (including lumbar spine, cervical spine, etc.), and are also called intervertebral body fusion prostheses (spinal cage).

An intervertebral disc is a disc of cartilage sandwiched between the vertebrae of the spine (backbone). It absorbs the body's load and shock between each vertebra, excluding part of the cervical vertebrae, and performs a buffering function to disperse shock like a spring. . At this time, the intervertebral disc holds the vertebrae from being separated, separates the two vertebrae to prevent the spinal nerves from being compressed, smoothes the range of the spinal joint holes, and plays a role in smoothing the movement of each vertebra.

These intervertebral discs are usually composed of the structure of the annulus fibrosus and the nucleus pulposus. The annulus fibrosus controls the movement of the spinal pieces, and the nucleus pulposus inside is composed of 70-80% water. It cushions or transmits vertical loads and shocks. In degenerative disc disease, the annulus fibrosus loses its ability to move and contain the nucleus pulposus, and its water content is reduced.

Therefore, these complex results result in diseases such as spinal stenosis, osteophyte formation, disc herniation, and nerve root compression. As a method of treating diseases caused by intervertebral discs, the disc between the damaged vertebrae of the human body is removed and then placed in the space between two adjacent vertebrae (hereinafter referred to as 'disc space in between two vertebrae'). One method is to replace the intervertebral disc with an implant. In other words, the purpose is to create as natural a state as possible through transplantation, and to restore the function of the spine by restoring the original distance between two adjacent vertebrae, which is the original height of the intervertebral disc.

These intervertebral disc implants generally have an appropriate thickness and anatomical shape to restore the original height of the intervertebral disc, have a hole formed to facilitate bone growth after death, and are firmly held at the end of the insertion device. A holding part is formed. Spinal interbody fusion surgery generally consists of the following procedures.

First, the intervertebral disc of the degenerated lumbar segment is removed and a fusion body and cage are inserted in its place. The cage secures space for fusion while preventing contact between vertebral bodies. Afterwards, the fusion segment is fixed to the posterior bone using pedicle screws and fusion connecting rods.

On the other hand, when the vertebral body has collapsed in a patient with a spinal tumor or metastatic cancer, it is difficult to restore spinal stability only through posterior device fixation using pedicle screws and steel rods. In this case, the collapsed vertebral body must be removed and a vertebral body replacement implant must be inserted to restore anterior spinal column stability. In patients with spinal metastatic cancer, the lesion at the surgical site grows again within a few days or weeks after such surgery, putting pressure on the spinal cord. As paralysis often occurs, new improvement measures are required to prevent this.

In addition, in patients who have suffered paralysis due to spinal tumor or spinal metastatic cancer compressing the spinal cord, the spinal cord is compressed, the tumor is removed, and the spinal cord is decompressed after a surgical approach for the purpose of maintaining the patient's walking ability, urination-defecation function, and relieving pain. Recovery of paralyzed spinal cord function is expected. However, due to the nature of tumors that continue to proliferate, the removed tumor or metastatic cancer cells often proliferate again in the surgical area within a short period of time, causing paralysis to worsen again, so improvement measures are required.

In addition, during spinal interbody fusion, BMP-2 (bone morphogenetic protein-2), an essential growth factor for bone formation, can itself induce differentiation into bone cells, and due to this property, it can be used in applications such as bone transplantation or bone regeneration. It is widely used in the field.

However, because BMP-2 is in liquid form, the inflammatory response that flows out to the surroundings and irritates unwanted soft tissues is a problem. In the case of anterior cervical fusion, this soft tissue inflammatory reaction causes airway obstruction, resulting in fatal complications of patient death, so extreme caution is required when using it.

The technical configuration described above is background technology to aid understanding of the present invention, and does not mean that it is a conventional technology widely known in the technical field to which the present invention pertains.

Korean Patent Publication No. 10-1950115 (Keimyung University Industry-Academic Cooperation Foundation) 2019. 02. 13. Korean Patent Publication No. 10-1045620 (Corentec Co., Ltd.) 2011. 06. 24. Korean Patent Publication No. 10-1845779 (Sewon Meditech Co., Ltd.) 2018. 03. 30.

Therefore, the technical problem to be achieved by the present invention is to treat orthopedic diseases and defects using biodegradable composite materials and devices used in medical kits for treating spinal diseases and other related musculoskeletal and nervous system diseases. It is for this purpose.

According to one aspect of the present invention, a case disposed in an area of the spine where an intervertebral disc is provided; And an implant including a biodegradable porous carrier provided in the inner space of the case and absorbing liquid bone morphogenetic protein and dissolving it into the treatment area can be provided. The carrier is provided as a network tissue and can absorb the bone morphogenetic protein to prevent the bone morphogenetic protein from leaking to the outside of the case except for the treatment area. The carrier may include a cancellous bone allograft. The carrier is porous and can absorb the bone morphogenetic protein to prevent the bone morphogenetic protein from leaking out of the case except for the treatment area. The carrier may include porous hydroxyapatite. The carrier may include an absorbable collagen sponge (ACS). The case may be made of a material containing polyetheretherketone (PEEK) or cortical bone allograft. The bone morphogenetic protein may include BMP-2. The case and the carrier can be prepared integrally using 3D printing. The carrier may be made of a biodegradable porous polymer.

Embodiments of the present invention provide an orthopedic disease treatment kit used to treat spinal diseases and other related musculoskeletal and nervous system diseases, which satisfies biocompatibility and biodegradability without rejection related to foreign substances in the human body, and is used to treat diseases. Qualitatively improved treatment can be achieved by using various biologically active substances appropriate for the condition.

Figure 1 is a diagram schematically showing an implant equipped with a carrier that prevents leakage of bone morphogenetic protein according to an embodiment of the present invention.
Figure 2 is a schematic exploded perspective view of Figure 1.
FIG. 3 is a carrier applied to this embodiment. FIG. 3(a) shows a carrier provided with a network structure, FIG. 3(b) shows a carrier provided with a porous structure, and FIG. 3(c) shows a carrier provided with a porous structure. is a diagram showing a carrier prepared with an absorbable collagen sponge.
Figure 4 is a diagram schematically showing an implant used for the anterior lumbar spine, which is an implant equipped with a carrier that prevents leakage of bone morphogenetic protein according to an embodiment of the present invention.
Figure 5 is a diagram schematically showing another implant used for the anterior lumbar spine, which is an implant equipped with a carrier that prevents leakage of bone morphogenetic protein according to an embodiment of the present invention.
Figure 6 is a diagram schematically showing an implant that prevents the proliferation of cancer cells according to an embodiment of the present invention.
FIG. 7 is a diagram schematically showing the implant for preventing the proliferation of cancer cells shown in FIG. 6 coupled to the vertebral body.
Figure 8 is a diagram schematically showing an implant that prevents the proliferation of cancer cells according to an embodiment of the present invention.
Figure 9 is a diagram schematically showing a tumor compressing the spinal cord, the compressed spinal cord, and the dura mater surrounding it according to an embodiment of the present invention.
Figure 10 is a diagram schematically showing that the anticancer substance eluting filling unit for spinal decompression surgery according to an embodiment of the present invention is provided in the space between the vertebral body and the dura or the epidural space.
Figure 11 is a diagram schematically showing an anticancer substance eluting filling unit for spinal decompression applied to an embodiment of the present invention.

Hereinafter, specific details for carrying out the present invention will be described based on examples with reference to the drawings. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention. It should be understood that the various embodiments of the present invention are different from one another but are not necessarily mutually exclusive. For example, specific shapes, structures and characteristics described herein with respect to one embodiment may be implemented in other embodiments without departing from the spirit and scope of the invention. Additionally, it should be understood that the location or arrangement of individual components within each disclosed embodiment may be changed without departing from the spirit and scope of the invention. Accordingly, the detailed description that follows is not intended to be taken in a limiting sense, and the scope of the invention is limited only by the appended claims, together with all equivalents to what those claims assert if properly described. Similar reference numbers in the drawings refer to identical or similar functions across various aspects. In order to fully understand the present invention, its operational advantages, and the objectives achieved by practicing the present invention, reference should be made to the accompanying drawings illustrating preferred embodiments of the present invention and the contents described in the accompanying drawings.

Hereinafter, the present invention will be described in detail by explaining preferred embodiments of the present invention with reference to the accompanying drawings. The same reference numerals in each drawing indicate the same member.

Figure 1 is a diagram schematically showing an implant equipped with a carrier for preventing leakage of bone morphogenetic protein according to an embodiment of the present invention, Figure 2 is a schematic exploded perspective view of Figure 1, and Figure 3 is the present embodiment. As a carrier applied to, Figure 3 (a) shows a carrier made of network tissue, Figure 3 (b) shows a carrier prepared as porous, and Figure 3 (c) shows a carrier made of absorbable collagen sponge. This is a drawing showing a carrier.

As shown in these figures, the implant 1 equipped with a carrier for preventing leakage of bone morphogenetic protein according to the present embodiment includes a case 10 disposed in the area of the spine where the intervertebral disc is provided, and a case 10. It is provided in the prosthetic receiving space 11 and is provided with a carrier 20 that absorbs the liquid bone formation protein 30 and allows it to be eluted to the treatment area.

The case 10 is placed in the space (intervertebral body) between two adjacent vertebrae and serves to restore the function of the spine by restoring the original distance between the two adjacent vertebrae, which is the original height of the intervertebral disc.

In this embodiment, the case 10 is provided with a receiving space 11, as shown in FIG. 2, and this receiving space 11 contains a carrier ( 20) can be provided.

Additionally, in this embodiment, as shown in FIG. 2, a plurality of fixing protrusions 12 may be provided to be spaced apart from the upper and lower surfaces of the case 10. In this embodiment, the plurality of fixing protrusions 12 may respectively engage with two adjacent vertebrae to fix the position of the case 10.

Furthermore, in this embodiment, the case 10 may be made of a material containing PEEK (polyetheretherketone) or cancellous bone allograft. In this embodiment, when the case 10 is made of PEEK material, it has an elastic modulus similar to that of the cortical bone of the vertebral body, which has advantageous characteristics in distributing load and stress, and thus provides stability with a lower sinking frequency than a titanium cage biomechanically. It has the advantage of maintaining spinal fissure and having a high intervertebral body fusion rate.

As shown in FIG. 1, the carrier 20 is provided inside the case 10 and contains liquid bone morphogenetic protein 30 to prevent the liquid bone morphogenetic protein 30 from leaking to areas other than the treatment area. You can prevent it from going out.

That is, in this embodiment, the carrier 20 is provided in a network or porous form to absorb and contain the liquid bone morphogenetic protein 30, thereby preventing the liquid bone morphogenetic protein 30 from leaking to areas other than the treatment area. You can prevent it from going out.

In this embodiment, the carrier 20 is made of a biodegradable porous polymer and can be prepared by containing liquid bone morphogenetic protein, which is a bioactive material.

In this embodiment, biodegradability generally means decomposition through hydrolysis and/or oxidative decomposition, or decomposition within an appropriate time period enzymatically or under the influence of microorganisms such as bacteria, yeast, fungi, and algae.

In this embodiment, “porosity” refers to the arrangement of pores, channels, and cages, and the arrangement of pores, channels, and cages may be irregular, regular, or periodic. Additionally, the pores or channels may be separate or interconnected and may be one-dimensional, two-dimensional, or three-dimensional. In this embodiment, the specific type of the biodegradable porous polymer is not particularly limited as long as it is a particle capable of forming a porous structure, but may include a natural polymer or a synthetic polymer.

In this embodiment, the natural polymer may be collagen, hyaluronic acid, gelatin, or chitosan, and the synthetic polymer may be PLGA (poly(lactic-co-glycolic acid)), PGA ( It may be poly(glycolic acid)), PLA (poly(lactic acid)), or PEG (poyethylene glycol), but is not limited thereto.

In this embodiment, the biodegradable porous polymer exhibits the above-described porous form, so that liquid osteogenic protein can be effectively contained in the pores, channels, and cages.

In this embodiment, the carrier 20 is provided as a network tissue, as shown in (a) of FIG. 3, and absorbs the liquid bone morphogenetic protein 30 to form bone outside the case 10 except for the treatment area. It can prevent protein (30) from leaking.

In this embodiment, the carrier 20 may include a cancellous bone allograft. In addition, in this embodiment, the carrier 20 is porous, as shown in (b) of FIG. 3, and absorbs the liquid bone morphogenetic protein 30 to form bone outside the case 10 except for the treatment area. It can prevent protein (30) from leaking.

In this embodiment, the carrier 20 may include porous hydroxyapatite. Furthermore, in this embodiment, the carrier 20, as shown in (c) of FIG. 3, is provided as an absorbable collagen sponge (ACS) to absorb the liquid bone morphogenetic protein 30, thereby removing the area except for the treatment area. It is possible to prevent the bone morphogenetic protein 30 from leaking to the outside of the case 10.

And in this embodiment, the carrier 20 can be prepared integrally with the case 10 using 3D printing. In this case, the carrier 20 may be prepared containing calcium carbonate or calcium phosphate, which are osteogenesis-friendly materials.

Meanwhile, in this embodiment, the internal structure of the carrier 20 may be prepared differently. In other words, the network tissue or porous structure disposed in an area other than the treatment area may be provided more densely than the network tissue or porous structure placed in the treatment area.

For example, the network or porous structure disposed in the edge area of the case 10 may be prepared to have a denser structure than the network or porous structure in the area of the carrier 20 disposed in the center of the case 10. .

In this case, it is possible to more effectively prevent the bone morphogenetic protein 30 from leaking to the outside of the case 10 except for the treatment area. The bone morphogenetic protein 30 is prepared in a liquid form and may be prepared by inserting it into the above-described carrier 20 by the operator during surgery, or it may be contained in the carrier 20 and placed inside the case 10. It may be provided.

In this embodiment, the bone morphogenic protein 30 may include bone morphogenic protein-2 (BMP-2). BMP-2 acts as a growth and differentiation factor in the body, and acts broadly at all stages of bone formation, from mesenchymal stem cells to differentiation into osteoblasts, and is known to promote new bone formation, making it the most effective in clinical practice. It is widely applied.

In this embodiment, bone morphogenetic protein 30 is selected from the group consisting of BMP-4, BMP-5, BMP-6, BMP-7, BMP-9, BMP-10, BMP-12, and BMP-13 in addition to BMP-2. There may be one or more selected types. Additionally, in this embodiment, the bone morphogenetic protein 30 may be contained in the carrier 20 in consideration of the size of the patient's treatment area or case 10.

Figure 4 is a diagram schematically showing an implant used for the anterior lumbar spine as an implant equipped with a carrier for preventing leakage of bone morphogenetic protein according to an embodiment of the present invention, and Figure 5 is a diagram showing an implant according to an embodiment of the present invention. This is a diagram schematically showing another implant used for the anterior lumbar spine, which is an implant equipped with a carrier that prevents leakage of bone morphogenetic proteins.

This embodiment can also be applied to implants used for anterior lumbar surgery, as shown in FIGS. 4 and 5. For reference, the previously described embodiment is an implant used for the cervical spine. Additionally, in this embodiment, the above-described carrier 20 and bone morphogenetic protein 30 may be equally applied. As discussed above, in this embodiment, the carrier disposed inside the case absorbs the liquid bone morphogenetic protein and allows it to dissolve in the treatment area, thereby preventing the bone morphogenetic protein from leaking to the outside of the case except for the treatment area.

As a result, liquid bone morphogenetic protein can be prevented from flowing out to the periphery of the case and irritating unwanted soft tissues, causing an inflammatory response. In the case of anterior cervical fusion surgery, the risk of this soft tissue inflammatory reaction causing airway obstruction can be prevented.

Figure 6 is a diagram schematically showing an implant that prevents the proliferation of cancer cells according to an embodiment of the present invention.

As shown in FIG. 6, the implant 1 for preventing the proliferation of cancer cells according to this embodiment includes a case 10 that is inserted between adjacent vertebral bodies to replace the vertebral body, and an anticancer substance in the case 10. It is provided with an anti-cancer substance coating portion 20 that is coated to dissolve and suppresses the proliferation of cancer cells at the surgical site.

The case 10 is inserted between adjacent vertebral bodies to replace the vertebral bodies, and serves to restore the function of the vertebral bodies by restoring the original distance between the two adjacent vertebral bodies, which is the original height of the vertebral bodies.

In this embodiment, the case 10 may have a cylindrical shape with an empty interior, as shown in FIG. 6 . That is, in this embodiment, the case 10 may be a mesh cage having the shape of a hollow cylindrical network.

In this embodiment, case 10 may be made of titanium. Titanium is non-toxic and has excellent biostability and biocompatibility.

In this embodiment, the case 10 is provided with an internal space 11, and bone morphogenetic protein or a carrier containing it may be provided in the internal space 11.

Additionally, in this embodiment, the case 10 may be made of a material containing PEEK (polyetheretherketone) or cancellous bone allograft. In this embodiment, when the case 10 is made of PEEK material, it has an elastic modulus similar to that of the cortical bone of the vertebral body, which has advantageous characteristics in distributing load and stress, and thus provides stability with a lower sinking frequency than a titanium cage biomechanically. It has the advantage of maintaining spinal fissure and having a high intervertebral body fusion rate.

And in this embodiment, as shown in FIG. 6, a plurality of fixing protrusions 12 may be provided to be spaced apart from the upper and lower surfaces of the case 10. In this embodiment, the plurality of fixing protrusions 12 may respectively engage with two adjacent vertebral bodies to fix the position of the case 10.

The anti-cancer substance coating portion 20 is provided to elute the anti-cancer substance into the case 10, thereby preventing cancer cells from proliferating at the surgical site and causing paralysis to worsen due to compression of the spinal cord within a short period of time after surgery.

In other words, if the vertebral body has collapsed in a patient with spinal metastatic cancer, it is difficult to restore spinal stability only through posterior device fixation using pedicle screws and steel rods. In this case, the collapsed vertebral body must be removed and a vertebral body replacement implant inserted to restore anterior spinal stability. In patients with spinal metastatic cancer, the lesion at the surgical site grows again within a few days to several weeks after such surgery, compressing the spinal cord and causing paralysis. However, as in this embodiment, an anticancer material coating portion 20 is provided on the case 10. This will prevent paralysis from worsening at the surgical site.

In this embodiment, the anti-cancer substance coating portion 20 may be provided in an area excluding the internal space 11 of the case 10, as shown in FIG. 6. It is not limited to this and may be selectively provided in the internal space 11.

Additionally, in this embodiment, the anticancer substance may include diethylstilbestrol (DES) or Taxol. Diethylstilbesterone does not cause cancer cell proliferation, but it can prevent cancer cells from necrosis by reducing their responsiveness to anticancer drugs.

Furthermore, in this embodiment, the anti-cancer substance coating portion 20 can be prepared by spraying an anti-cancer substance onto the case 10, and the case 10 is immersed in a liquid anti-cancer substance so that the anti-cancer substance is applied to the case 10. This can be prepared. In this embodiment, the anti-cancer substance coating portion 20 may be provided by forming an anti-cancer substance into a film to cover the outer surface of the case 10. In addition to the above-described method, the anti-cancer substance coating portion 20 may be applied to the case 10. Various methods can be applied to form .

And in this embodiment, the degree of elution of the anti-cancer substance can be controlled by the thickness of the anti-cancer substance coating portion 20. Additionally, in this embodiment, the anti-cancer substance is bound to the surface of the case 10 through a chemical bond, so that the degree to which the anti-cancer substance is released can be controlled depending on the degree to which the chemical bond is broken.

In this embodiment, the method of manufacturing an implant that prevents the proliferation of cancer cells includes preparing a case 10 that is inserted between adjacent vertebral bodies to replace the vertebral bodies, and coating the case 10 so that anti-cancer substances are eluted for surgery. It includes the step of providing an anti-cancer substance coating portion 20 that inhibits the proliferation of cancer cells in the area.

In this embodiment, the step of preparing the anti-cancer substance coating portion 20 may be performed by the above-described method, that is, spraying or dipping the anti-cancer substance into the case 10, or wrapping the outer surface of the case 10 with a film.

Meanwhile, in this embodiment, a biodegradable porous polymer is provided inside the case 10, and the carrier is supported by a method of carrying a stimulus-sensitive polymer and a bioactive material including an anticancer agent and a cytostatic drug on the biodegradable porous polymer. It can prevent the proliferation of cancer cells.

In this embodiment, the biodegradable porous polymer exhibits the above-described porous form, so that bioactive substances such as anticancer drugs and cell proliferation inhibitors and stimulus-sensitive polymers can be effectively loaded into the pores, channels, and cages.

In this embodiment, the anticancer drugs and cytostatic drugs are Doxorubicin, Epirubicin, Gemsitabin, Cisplatin, Carboplatin, Procarbazine, and Cyclophos. Cyclophosphamide, Dactinomycin, Daunorubicin, Etoposide, Tamoxifen, Mitomycin, Bleomycin, Plicomycin , Transplatinum, Vinblastine, and Methotrexate, but is not limited thereto.

In this embodiment, the stimulus-sensitive polymer refers to a polymer that can be dissolved/decomposed in response to various internal and external stimuli such as temperature, pH, etc., such as gelatin, PCL (polycaprolactone), chitosan, and PNIPAAm. (Poly(NˇIsopropylacrylamide)) and/or HEMA (2-hydroxyethyl(methacrylate)), but is not limited thereto. In this embodiment, the stimulus-sensitive polymer can be dissolved/decomposed in the body temperature range of 36-40°C, so anticancer drugs and cytostatic drugs can be easily released from the biodegradable porous polymer.

Figure 8 is a diagram schematically showing an implant that prevents the proliferation of cancer cells according to another embodiment of the present invention.

As shown in FIG. 8, the implant 1a, which prevents the proliferation of cancer cells in this embodiment, includes a case 10 and the above-described anti-cancer material coating portion 20 provided on the case.

The case 10 is inserted between adjacent vertebral bodies to replace the vertebral bodies, and may have a cylindrical shape, as shown in FIG. 8.

In this embodiment, as shown in FIG. 8, a plurality of fixing protrusions 12 may be provided to be spaced apart from the upper and lower surfaces of the case 10. In this embodiment, the plurality of fixing protrusions 12 may respectively engage with two adjacent vertebrae to fix the position of the case 10.

Additionally, in this embodiment, the case 10 is provided with a fastening hole 13, as shown in FIG. 8, and the plate 30 can be detachably screwed to the fastening hole 12.

Furthermore, in this embodiment, the case 10 is provided with a plurality of through holes 14 to induce bone formation. In other words, it is possible to accommodate autograft or allograft while promoting the formation of new bone through the plurality of through holes (14).

The above-described embodiment may be applied as is to the anti-cancer substance coating portion 20.

As discussed above, in this embodiment, an anti-cancer material coating is provided to allow the anti-cancer material to elute in a case that is inserted between adjacent vertebral bodies to replace the vertebral bodies, so that cancer cells proliferate at the surgical site and paralysis occurs again due to compression of the spinal cord within a short period of time after surgery. It can be prevented from getting worse.

Figure 9 is a diagram schematically showing a tumor compressing the spinal cord, the compressed spinal cord, and the dura surrounding it, and Figure 10 shows the space between the vertebral body and the dura as the anti-cancer substance eluting filling unit for spinal decompression surgery according to an embodiment of the present invention. Or, it is a drawing schematically showing what is provided in the epidural space.

The anti-cancer material filling unit 1 for spinal decompression surgery according to this embodiment removes the tumor 400 compressing the spinal cord 200 shown in FIG. 9, and after decompressing the spinal cord 200, the filling unit 1 shown in FIG. 10 As shown, it may be provided in the space between the vertebral body 100 and the dura mater 300 or in the space outside the dura mater 300.

In this embodiment, the anti-cancer substance filling unit 1 may be made of a biodegradable porous polymer, and the anti-cancer drug or a porous structure in the form of a fine powder may be prepared in a form in which the anti-cancer agent or a porous structure in the form of a fine powder enters the mixture in the form of a gel and is distributed.

In this embodiment, the biodegradable porous polymer exhibits the above-described porous form, so that bioactive substances such as anticancer drugs and cell proliferation inhibitors and stimulus-sensitive polymers can be effectively loaded into the pores, channels, and cages.

In this embodiment, the anticancer drugs and cytostatic drugs are Doxorubicin, Epirubicin, Gemsitabin, Cisplatin, Carboplatin, Procarbazine, and Cyclophos. Cyclophosphamide, Dactinomycin, Daunorubicin, Etoposide, Tamoxifen, Mitomycin, Bleomycin, Plicomycin, It may be one or more selected from the group consisting of Transplatinum, Vinblastine, and Methotrexate, but is not limited thereto.

In this embodiment, the stimulus-sensitive polymer refers to a polymer that can be dissolved/decomposed in response to various internal and external stimuli such as temperature, pH, etc., such as gelatin, PCL (polycaprolactone), chitosan, and PNIPAAm. (Poly(NˇIsopropylacrylamide)) and/or HEMA (2-hydroxyethyl(methacrylate)), but is not limited thereto. In this embodiment, the stimulus-sensitive polymer can be dissolved/decomposed in the body temperature range of 36-40°C, so anticancer drugs and cytostatic drugs can be easily released from the biodegradable porous polymer.

Additionally, in this embodiment, the anti-cancer material filling unit 1 for spinal decompression surgery may be made of an absorbable gelatin sponge. In this embodiment, the absorbable gelatin sponge may be prepared in a form that includes a gel form.

Meanwhile, as shown in FIG. 11, the anti-cancer substance eluting filling unit 1 for spinal decompression surgery according to the present embodiment is provided with a base body 10 and an anti-cancer substance eluting device provided inside the base body 10 to elute the anti-cancer substance. It is provided with unit 20.

The base body 10 may be provided in a space between the vertebral body 100 and the dura mater 300 or in a space outside the dura mater 300.

In addition, in this embodiment, the base body 10 of the anticancer substance eluting filling unit 1 is made of a soft material containing silicon, so that the area in contact with the vertebral body 100, the dura mater 300, and the space outside the dura mater 300 is deformed. (100) or the dura mater (300), the pressure applied to the space area outside the dura mater (300) can be reduced. In this embodiment, the base body 10 may be provided with a plurality of holes to discharge anti-cancer substances.

Furthermore, in this embodiment, the base body 10 of the anti-cancer substance eluting filling unit 1 is provided in a network or porous form, so that when the anti-cancer substance eluting unit 20 is provided in liquid form, it absorbs the liquid anti-cancer substance and transfers the anti-cancer substance to the surgical site. can be released. In this embodiment, the base body 10 of the anticancer substance eluting filling unit 1 may be made of a material including bone graft of reticular tissue, porous hydroxyapatite, or absorbable collagen sponge (ACS). .

As shown in FIG. 9, the anticancer substance eluting filling unit 1 is provided in the base body 10, and the anticancer substance eluting unit 20 elutes the anticancer substance into the surrounding area of the base body 10 to prevent spinal metastatic cancer. After decompressing the spinal cord 200 through a surgical approach in a patient who has suffered paralysis due to compression of the spinal cord 200, it is possible to prevent cancer cells from proliferating again at the surgical site within a short period of time and worsening the paralysis.

In this embodiment, the anti-cancer substance eluting filling unit (1) and the anti-cancer substance eluting unit (20) are in the form of a paste such as Floseal, which is commonly used as a hemostatic agent, or a gel-sol (such as a surgical sealant and adhesive). It can be prepared in gel-sol form or in plastic clay form (putty form). In this embodiment, the surgical sealant and adhesive may include duraseal.

Additionally, in this embodiment, the anticancer substance eluting filling unit 1 and the anticancer substance eluting unit 20 may be provided in a liquid state when the base body 10 is provided in a network structure or porous form capable of containing liquid. In this embodiment, when the base body 10 is provided in a network structure or porous form capable of containing liquid, the internal structure of the base body 10 of the anticancer substance eluting filling unit 1 may be prepared differently. In other words, the network tissue or porous structure disposed in the area other than the treatment area is provided more densely than the network tissue or porous structure placed in the treatment area, so that the degree of elution of the anticancer substance can be controlled. For example, the network structure or porous structure of the area of the base body 10 of the anticancer substance eluting filling unit 1 disposed at the edge area is the network structure of the area of the base body 10 of the anticancer substance eluting filling unit 1 disposed at the center. It can be prepared to have a less dense structure than a tissue or porous structure. In this case, there is an advantage in being able to supply more anti-cancer substances to the treatment area. In this embodiment, the treatment area is the upper and lower areas of the internal space 11 provided in the base body 10 of the anticancer substance eluting filling unit 1, and the through hole provided in the wall of the base body 10 of the anticancer substance eluting filling unit 1. It may be an area facing.

In addition, in this embodiment, no network tissue or porous structure is provided in the area other than the area of the base body 10 of the anti-cancer substance eluting filling part 1 corresponding to the treatment area, so that the anti-cancer substance is supplied outside the area excluding the treatment area. You can prevent it from happening.

In this embodiment, after providing a network tissue or porous structure in the anti-cancer substance-eluting filling unit (1) base body (10), the anti-cancer substance-eluting filling unit (1) base body (10) is used in the area excluding the area corresponding to the treatment area during surgery. ) can be blocked with a barrier film that is harmless to the human body, preventing anticancer substances from being supplied to areas other than the treatment area. The barrier film in this embodiment includes known films used in medical surgery.

In this embodiment, the anticancer substance provided in the anticancer substance elution filling unit 1 and the anticancer substance elution unit 20 may include paclitaxel or various cell proliferation inhibitory drugs.

Below, the method of using this embodiment will be briefly described.

First, the patient is given general anesthesia, the patient's waist is exposed in a prone position, and a long skin incision is made along the center of the back of the waist. The length of the incision is determined depending on the scope of the surgery.

Next, the posterior arch of the spine is resected, part of the posterior joint is removed, the thickened ligamentum flavum is removed, and nerve decompression is performed to prevent the spinal nerves (200) from being compressed.

Next, the ligament that protrudes and compresses the nerve is excised, and disc removal surgery (100) is performed to remove the intervertebral disc in the relevant area. When performing posterolateral fusion surgery, the disc 100 is not removed.

Thereafter, the anticancer substance eluting filling unit for spinal decompression surgery of this embodiment is inserted into the empty space provided by removing the disc 100 in the corresponding area.

Next, to compensate for spinal instability, posterior fixation using metal connecting rods and screws is performed, and bone grafting using autologous bone or artificial bone is performed to perform vertebral body fusion.

Lastly, the incised skin is sutured.

As such, the present invention is not limited to the described embodiments, and it is obvious to those skilled in the art that various modifications and changes can be made without departing from the spirit and scope of the present invention. Accordingly, such modifications or variations should be considered to fall within the scope of the claims of the present invention.

1: Bone morphogenetic protein carrier integrated implant
10: Case
11: Internal space
12: Fixed protrusion
20: carrier
30: Bone morphogenetic protein

Claims (3)

Case placed in the area of the spine where the intervertebral disc is located; and
An implant provided in the internal space of the case and comprising a biodegradable porous carrier that absorbs liquid bone morphogenetic protein and allows it to dissolve at the treatment site.
The method according to claim 1, wherein the carrier is an implant comprising at least one of a cancellous bone allograft, porous hydroxyapatite, and an absorbable collagen sponge.
The method according to claim 1, wherein the case is an implant made of a material containing PEEK (polyetheretherketone) or cancellous bone graft (cortical bone allograft).